Skip to main content
News

Eyeing $1B in annual sales, Emergent BioSolutions to buy Narcan maker Adapt for $735M | Fierce Pharma

By August 22, 2022No Comments
Emergent Logo

Emergent LogoEmergent BioSolutions is mobilizing its M&A war chest again. Hard on the heels of its $270 million deal for vaccine expert PaxVax, the frequent government contractor is buying Adapt Pharma and its opioid overdose-reversing drug Narcan.

The Maryland-based firm is paying $635 million upfront and up to $100 million for potential sales-based milestones through 2022. Narcan, the only FDA-approved nasal spray of naloxone, has been on the market since 2016. Emergent  estimates the drug will contribute $200 million to $220 million to the company’s top line in 2019. In addition to Narcan and an opioid overdose-focused pipeline, about 50 Adapt employees will come aboard Emergent.

 

{iframe}https://www.fiercepharma.com/pharma/eyeing-1b-annual-sales-emergent-biosolutions-to-buy-narcan-maker-adapt-for-735m{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.